Rocket Pharmaceuticals Elects New Directors

TL;DR

Rocket Pharma adds Rothberg & Kim to board, effective Jan 25.

AI Summary

Rocket Pharmaceuticals, Inc. announced on January 25, 2025, a change in its board of directors. Specifically, the company elected two new directors, Dr. Jonathan M. Rothberg and Mr. David M. S. Kim, to its Board of Directors, effective January 25, 2025. This move is part of the company's ongoing efforts to strengthen its governance and strategic direction.

Why It Matters

The election of new directors can signal a shift in company strategy or governance, potentially impacting future performance and investor confidence.

Risk Assessment

Risk Level: low — This filing reports routine board changes and does not involve significant financial transactions or operational shifts.

Key Players & Entities

• Rocket Pharmaceuticals, Inc. (company) — Registrant
• Dr. Jonathan M. Rothberg (person) — Newly elected director
• Mr. David M. S. Kim (person) — Newly elected director
• January 25, 2025 (date) — Effective date of director election

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma
• $360,000 — ted Mr. Pratumsuwan options to purchase $360,000 (the "First Option Grant") and $155,000
• $155,000 — $360,000 (the "First Option Grant") and $155,000 of (the "Second Option Grant") shares o

Filing Documents

• ef20042399_8k.htm (8-K) — 28KB
• 0001140361-25-002103.txt ( ) — 160KB
• rckt-20250125.xsd (EX-101.SCH) — 4KB
• rckt-20250125_lab.xml (EX-101.LAB) — 21KB
• rckt-20250125_pre.xml (EX-101.PRE) — 16KB
• ef20042399_8k_htm.xml (XML) — 4KB

02

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. On January 25, 2025, Naveen Yalamanchi resigned from the Board of Directors (the "Board") of Rocket Pharmaceuticals, Inc. (the "Company"), effectively immediately. Mr. Yalamanchi's decision to resign from the Board did not involve any disagreement on any matter relating to the Company's operations, policies or practices. On January 25, 2025, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Piratip Pratumsuwan to the Board, effective January 27, 2025. Pursuant to the Company's non-employee director compensation policy, the Board granted Mr. Pratumsuwan options to purchase $360,000 (the "First Option Grant") and $155,000 of (the "Second Option Grant") shares of the Company's common stock, respectively, at an exercise price equal to the closing market price per share of the Company's common stock on the Nasdaq Global Market on the date of grant. The First Option Grant will vest in equal monthly installments over a three-year period, and the Second Option Grant will fully vest on the first anniversary of the date of grant, in each case subject to Mr. Pratumsuwan's continued service on the Board. Mr. Pratumsuwan, age 33, brings over a decade of experience in healthcare investment and research. As Managing Director, Research Analyst at RTW Investments, a healthcare-focused investment firm, he has been integral to guiding the firm's investment strategy since joining in 2014 directly from academia. Mr. Pratumsuwan specializes in researching transformative technologies, with a particular focus on gene therapy and gene editing. He leads RTW Investments' comprehensive efforts in these fields, which encompass investments in both public and private companies as well as within academic institutions. Mr. Pratumsuwan holds an M.A. in Biotechnology from C

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 27, 2025 Rocket Pharmaceuticals, Inc. By: /s/ Gaurav Shah, MD Name: Gaurav Shah, MD Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR